What is Parion Sciences?
Parion Sciences is a development-stage biopharmaceutical company dedicated to the research, development, and commercialization of innovative therapies designed to restore the innate mucosal surface defense of the lung. Their science-driven approach specifically targets respiratory conditions that arise from defective mucosal host defense mechanisms. The company's pipeline includes promising products such as ENAC Pulmonary, tPAD, and various mucolytic agents, positioning them to address critical unmet needs in patients suffering from chronic respiratory ailments.
How much funding has Parion Sciences raised?
Parion Sciences has raised a total of $3M across 1 funding round:
Grant
$3M
Grant (2014): $3M with participation from Cystic Fibrosis Foundation
Key Investors in Parion Sciences
Cystic Fibrosis Foundation
The Cystic Fibrosis Foundation is a leading non-profit organization dedicated to finding a cure for cystic fibrosis and ensuring individuals with CF can live long, productive lives. Their investment in Parion Sciences highlights a strategic focus on advancing therapies for related respiratory conditions.
What's next for Parion Sciences?
With the recent infusion of capital, Parion Sciences is poised to accelerate its clinical development programs and advance its pipeline of lung therapies. The major strategic investment suggests a focus on scaling operations, potentially expanding clinical trial reach, and preparing for future commercialization efforts. This funding will be instrumental in navigating the complex regulatory pathways and bringing their innovative treatments to patients in need.
See full Parion Sciences company page
